MIDAMOX FOR CATS- imidacloprid and moxidectin solution

Midamox for Cats by

Drug Labeling and Warnings

Midamox for Cats by is a Animal medication manufactured, distributed, or labeled by MWI/VetOne, Norbrook Laboratories Limited, Norbrook Manufacturing Ltd. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

SPL UNCLASSIFIED SECTION

Topical Solution

Once-a-month topical solution for cats for the prevention of heartworm disease, kills adult fleas, is indicated for the treatment of flea infestations, as well as the treatment and control of ear mite infestations and intestinal parasite infections in cats and kittens 9 weeks of age and older and that weigh at least 2 lbs.

Once-a-month topical solution for ferrets for the prevention of heartworm disease, kills adult fleas, and is indicated for the treatment of flea infestations. Indicated for ferrets that weigh at least 2 lbs.

CAUTION:

Federal (U.S.A.) Law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION:

Midamox for Cats (10 % imidacloprid + 1 % moxidectin) is a colorless to yellow ready-to-use solution packaged in single-dose applicators for topical treatment of cats. The formulation and dosage schedule are designed to provide a minimum of 4.5 mg/lb (10.0 mg/kg) imidacloprid and 0.45 mg/lb (1.0 mg/kg) moxidectin based on body weight.

Imidacloprid is a chloronicotinyl nitroguanidine insecticide. The chemical name of imidacloprid is 1-[(6-Chloro-3-pyridinyl) methyl]-N-nitro-2-imidazolidinimine. Moxidectin is a semisynthetic macrocyclic lactone endectocide derived from the actinomycete Streptomycetes cyaneogriseus noncyanogenus.

The chemical name of moxidectin is [6R, 23E, 25S(E)]-5-O-Demethyl -28-deoxy-25-(1,3-dimethyl-1-butenyl)-6,28-epoxy-23(methoxyimino) milbemycin B.

INDICATIONS:

Midamox for Cats is indicated for the prevention of heartworm disease caused by Dirofilaria immitis. Midamox for Cats kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations. Midamox for Cats is also indicated for the treatment and control of ear mite (Otodectes cynotis) infestations and the following intestinal parasites:

Intestinal Parasite		Intestinal Stage
		Adult	Immature Adult	Fourth; Stage; Larvae
Hookworm Species	Ancylostoma tubaeforme	X	X	X
Roundworm Species	Toxocara cati	X		X

WARNINGS:

Do not use on sick, debilitated, or underweight cats (see ADVERSE REACTIONS). Do not use on cats less than 9 weeks of age or less than 2 lbs. body weight.

HUMAN WARNINGS:

Not for human use. Keep out of the reach of children. Children should not come in contact with the application site for 30 minutes after application.

Causes eye irritation. Harmful if swallowed. Do not get in eyes or on clothing. Avoid contact with skin. Exposure to the product has been reported to cause headache; dizziness; and redness, burning, tingling, or numbness of the skin.

Wash hands thoroughly with soap and warm water after handling.

If contact with eyes occurs, hold eyelids open and flush with copious amounts of water for 15 minutes. If eye irritation develops or persists, contact a physician. If swallowed, call poison control center or physician immediately for treatment advice. Have person sip a glass of water if able to swallow. Do not induce vomiting unless told to do so by the poison control center or physician. People with known hypersensitivity to benzyl alcohol, imidacloprid or moxidectin should administer the product with caution. In case of allergic reaction, contact a physician. If contact with skin or clothing occurs, take off contaminated clothing. Wash skin immediately with plenty of soap and water. Call a poison control center or physician for treatment advice.

The Safety Data Sheet (SDS) provides additional occupational safety information. For a copy of the Safety Data Sheet (SDS) or to report adverse reactions call 1-866-591-5777.

PRECAUTIONS:

Do not dispense dose applicators without complete safety and administration information.

Avoid oral ingestion. Cats may experience hypersalivation, tremors, vomiting and decreased appetite if Midamox for Cats is inadvertently administered orally or through grooming/licking of the application site.

The safety of Midamox for Cats has not been established in breeding, pregnant, or lactating cats.

The effectiveness of Midamox for Cats against heartworm infections (D. immitis) after bathing has not been evaluated in cats.

Use of this product in geriatric patients with subclinical conditions has not been adequately studied. Several otherwise healthy, thin geriatric cats experienced prolonged lethargy and sleepiness after using this drug. (See ADVERSE REACTIONS.)

ADVERSE REACTIONS:

Field Study: Following treatment with imidacloprid and moxidectin or an active control, cat owners reported the following post-treatment reactions:

* These three cats were from the same household and included one 13-yr-old cat in good health, one 15-yr-old FIV positive cat in good health, and one 15-yr-old, underweight cat in fair health. Lethargy was noted for 24 to 36 hrs after the first treatment only; one cat was unsteady at 48 hrs. These cats were not on other medications.
OBSERVATION	Imidacloprid + moxidectin n = 113	Active Control n = 38
Lethargy (protracted sleeping, poorly responsive)	3 cats* (2.7%)	None observed
Behavioral changes (e.g., agitated, excessive grooming, hiding, pacing, spinning)	9 cats (8.0%)	1 cat (2.6%)
Discomfort (e.g., scratching, rubbing, head-shaking)	5 cats (4.4%)	None observed
Hypersalivation (within 1 hour after treatment)	3 cats (2.7%)	None observed
Polydipsia	3 cats (2.7%)	None observed
Coughing and gagging	1 cat (0.9%)	None observed

During another field study, a 16-year-old cat with renal disease slept in the same place without moving for two days following application. (See PRECAUTIONS.)

Laboratory Effectiveness Studies: Imidacloprid and moxidectin was administered at the recommended dose to 215 cats in 20 effectiveness studies. One random-sourced cat exhibited signs consistent with either moxidectin toxicity or viral respiratory disease and died 26 hours after product application; necropsy findings were inconclusive as to the cause of death. A second cat that became ill 3 days after application of imidacloprid and moxidectin responded to treatment for respiratory infection and completed the study. A third cat became ill on day 3 and died with signs and lesions attributable to panleukopenia on day 7 after moxidectin application.

Post-Approval Experience: The following adverse events are based on post-approval adverse drug experience reporting. Not all adverse reactions are reported to FDA CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using this data. The following adverse events in cats are listed in decreasing order of reporting frequency: hypersalivation, depression/ lethargy, application site reactions (alopecia, pruritus, lesions, and erythema), decreased appetite, vomiting, hyperactivity, ataxia, trembling, and behavior disorder (hiding).

In some cases death has been reported.

In humans, ocular and dermal irritation, nausea, numbness or tingling of the mouth and lips, anaphylaxis, pruritus, vomiting, and tongue/taste abnormalities have been reported following exposure to this product.

Contact Information:

To report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact 1-866-591-5777.

For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at www.fda.gov/reportanimalae.

DOSAGE AND ADMINISTRATION:

The recommended minimum dose is 4.5 mg/lb (10.0 mg/kg) imidacloprid and 0.45 mg/lb (1.0 mg/kg) moxidectin, once a month, by topical administration.

Do not apply to irritated skin.

1. 1. Remove the applicator from the outer pouch using scissors or fold along diagonal line to expose nick; tear back at nick. As specified in the following table, administer the entire contents of the Midamox for Cats (imidacloprid and moxidectin) applicator that correctly corresponds with the body weight of the cat.
   

   * Cats over 18 lbs. should be treated with the appropriate combination of Midamox for Cats applicators.
   Cat (lbs.)	Midamox for Cats	Volume (mL)	Imidacloprid (mg)	Moxidectin (mg)
   2–5	Midamox 5	0.23	23	2.3
   5.1–9	Midamox 9	0.4	40	4
   9.1–18*	Midamox 18	0.8	80	8

2. Hold the applicator upright.
3. Tap the narrow part of the applicator to ensure the contents remain within the main body of the applicator.
   
4. Twist or snap back the tip.
5. Part the hair on the back of the cat's neck at the base of the head in front of the shoulder blades, until the skin is visible. Place the tip of the applicator on the skin and squeeze the applicator several times to empty its contents completely and directly onto the skin in one spot.
   

Do not get this product in the cat's mouth or eyes or allow the cat to lick the application site for 30 minutes. Treatment at the base of the head will minimize the opportunity for ingestion by grooming. In households with multiple pets, keep animals separated to prevent licking of the application site.

Stiff, matted hair or a damp, oily appearance of the hair may be observed at the application site on some cats. This is temporary and does not affect the safety and effectiveness of the product.

Heartworm Prevention: For prevention of heartworm disease, Midamox for Cats should be administered at one-month intervals. Midamox for Cats may be administered year-round or at a minimum should start one month before the first expected exposure to mosquitoes and should continue at monthly intervals until one month after the last exposure to mosquitoes. If a dose is missed and a 30-day interval between doses is exceeded, administer Midamox for Cats immediately and resume the monthly dosing schedule. When replacing another heartworm preventative product in a heartworm prevention program, the first treatment with Midamox for Cats should be given within one month of the last dose of the former medication. At the discretion of the veterinarian, cats older than 6 months of age may be tested to determine the presence of existing heartworm infection before treatment with Midamox for Cats (See ADVERSE REACTIONS – Post-Approval Experience).

Flea Treatment: For the treatment of flea infestations, Midamox for Cats should be administered at one-month intervals. If the cat is already infested with fleas when the first dose of Midamox for Cats is administered, adult fleas on the cat will be killed. However, re-infestation from the emergence of pre-existing pupae in the environment may continue to occur for six weeks or longer after treatment is initiated. Cats treated with imidacloprid, including those with pre-existing flea allergy dermatitis have shown clinical improvement as a direct result of elimination of fleas from the cat.

Ear Mite Treatment: For the treatment of ear mites (Otodectes cynotis), Midamox for Cats should be administered once as a single topical dose. Monthly use of Midamox for Cats will control any subsequent ear mite infestations.

Intestinal Nematode Treatment: For the treatment and control of intestinal hookworm infections caused by Ancylostoma tubaeforme (adults, immature adults and fourth stage larvae) and roundworm infections caused by Toxocara cati (adults and fourth stage larvae), Midamox for Cats should be administered once as a single topical dose.

ANIMAL SAFETY:

Studies in Kittens: Imidacloprid and moxidectin was topically applied at 0, 1, 3, and 5X the maximum dose to 48 healthy 9-week-old kittens on days 0, 28, and 56. Lethargy was observed in 1 kitten from the 3X group and 1 from the 5X group on the day after initial treatment; the kitten from the 3X group was also disoriented and ataxic. One kitten from the 3X group had a slow pupillary light response two days after treatment and one had tremors the day after treatment. Hypersalivation was seen in one kitten from the 5X group approximately six hours post-treatment. One kitten from the 3X group was scratching at the treatment site 2 days after treatment. Slight cough was noted in 7 different kittens (2-0X, 2-1X, and 3-5X) during the 13-day period following the first treatment. Histopathology showed granulomatous inflammation at the treatment site in three 1X kittens. Causal relationship to the drug could not be determined. Pulmonary inflammation (1-5X) and lymphoid hyperplasia (2-1X, 4-3X) were seen in treated kittens. In a second study, imidacloprid and moxidectin was topically applied at 0, 1.7, 5.2 and 8.7X the maximum dose to 48 healthy 9-week-old kittens every two weeks for 6 doses. One kitten in the 8.7X group apparently ingested an unknown amount of the drug and developed the following clinical signs prior to euthanasia: mydriasis, salivation, depression, vomiting, unsteadiness, rapid to slow to difficult breathing, poor pupillary response, generalized tremors, inability to move, and nystagmus. Two kittens in the 5.2X group developed mydriasis, salivation, depression, squinting, and poor appetite. A kitten in the 1.7X group developed mydriasis.

Dose Tolerance Study: Eight healthy juvenile cats were topically dosed with a single application of imidacloprid and moxidectin at 10 times the recommended dose volume. Mild, transient hypersalivation occurred in two of the cats.

Oral Study in Cats: The oral safety of imidacloprid and moxidectin was tested in case of accidental oral ingestion. The maximum topical dose was orally administered to twelve healthy 9-week-old kittens. Hypersalivation (8 of 12 kittens) and vomiting (12 of 12 kittens) were observed immediately post-treatment. Tremors developed in one kitten within 1 hour, resolving without treatment within the next hour. All 12 kittens were either anorexic or had decreased appetite for at least 1 day following treatment. In 3 kittens, the anorexia or decreased appetite continued into the second week following treatment. There was a post-treatment loss of body weight in treated kittens compared to control kittens. In a pilot safety study using kittens younger in age and lighter in weight than allowed by product labeling, an 8-week-old kitten weighing 0.6 kg orally received 2X of the label topical dose (0.46 mL/kg). Immediately after dosing, it vomited, had labored breathing and slight tremors. Within 4 hours, it was normal, but was found dead on day 6. Necropsy could not determine the cause of death.

Study in Heartworm Positive Cats: Young adult cats were inoculated subcutaneously with third-stage D. immitis larvae. At 243-245 days post-infection, immunoserology and echocardiography were performed to identify cats with adult heartworm burdens similar to naturally-acquired infections. Two groups were treated topically with either imidacloprid and moxidectin at the label dose or placebo, once every 28 days, for three consecutive treatments. A third group was treated topically, once, with imidacloprid and moxidectin at 5X the label dose. Sporadic vomiting and labored breathing related to heartworm burden were observed in the treatment and control groups. There was no difference between treatment groups in the numbers of adult D. immitis recovered at study conclusion. No adverse reactions were associated with the topical application of imidacloprid and moxidectin to experimentally heartworm-infected cats.

FERRETS

Use only the 0.4 mL MIDAMOX for Cats in ferrets. The 0.23 mL size does not provide an effective dose and the 0.8 mL size could result in an overdose.

INDICATIONS:

For ferrets:

Midamox for Cats is indicated for the prevention of heartworm disease in ferrets caused by Dirofilaria immitis. Midamox for Cats kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations on ferrets.

WARNINGS:

Do not use on sick or debilitated ferrets.

PRECAUTIONS:

Do not dispense dose applicator tubes without complete safety and administration information.

The safety of Midamox for Cats has not been established in breeding, pregnant, and lactating ferrets.

Treatment of ferrets weighing less than 2.0 lbs (0.9 kg) should be based on a risk- benefit assessment.

The effectiveness of Midamox for Cats in ferrets weighing over 4.4 lbs (2.0 kg) has not been established.

ADVERSE REACTIONS:

Field Safety Study in Ferrets: Imidacloprid and moxidectin was topically administered to 131 client-owned ferrets at the recommended dose volume (0.4 mL). The ferrets ranged in age from 3 months to 7 years, and weighed between 0.5 and 1.86 kg (1.1 to 4.1 lbs). The dose of imidacloprid ranged between 21.5 to 80.2 mg/kg in this study. The dose of moxidectin ranged between 2.2 to 8.0 mg/kg in this study.

Adverse reactions in ferrets following treatment included: pruritus/scratching, scabbing, redness, wounds and inflammation at the treatment site; lethargy; and chemical odor. These adverse reactions resolved without additional therapy. Owners also reported stiffening of the hair at the treatment site, however, this is expected with application of a topical product and is not considered an adverse reaction.

Three human adverse reactions were reported. An owner's finger became red following skin contact with the product. One owner reported a headache caused by the chemical odor of the product. One owner reported a tingling sensation of the lips after kissing the treatment site.

Foreign Market Experience: Because the following events were reported voluntarily during post-approval use of the product in foreign markets, it is not always possible to reliably establish a causal relationship to drug exposure. Adverse events reported in ferrets topically treated with 0.4 mL imidacloprid + moxidectin for cats included: malaise, vomiting, diarrhea, shaking, mydriasis, hypersalivation with abnormal neurologic signs, seizures, death, generalized hematoma of the body, and alopecia at the treatment site. Adverse reactions in humans included: burning, tingling, numbness, bad taste in the mouth, dizziness, and headache.

ANIMAL SAFETY:

Ferrets: Imidacloprid and moxidectin was topically applied at 5X the recommended dose volume to six healthy 9-month-old ferrets on Study Days 0, 14, 28, and 42. Because the weights of the ferrets in this study ranged from 2.0 to 4.0 lb (0.9 kg to 1.8 kg), ferrets received a range of dosages from 51.0 to 106.9 mg/lb (112 to 235 mg/kg) of imidacloprid and 5 to 10.5 mg/lb (11 to 23 mg/kg) of moxidectin. The following abnormal clinical signs were reported during the study: wet, matted, and/or greasy appearance to the hair, shaking of the head and/or body, rubbing of dose site on cage, and shedding. Slight increases in phosphorous, potassium, aspartate aminotransferase (AST), and glucose were seen during the study, however, no clinical signs related to these bloodwork changes were reported.

Oral Safety Study: Imidacloprid and moxidectin was orally administered at the recommended dose volume (0.4 mL) to eight healthy ferrets on Study Day 0. Ferrets were 78 to 101 days old (11.1 to 14.4 weeks) and weighed between 1.1 to 1.8 lb (0.5 to 0.8 kg) body weight on the day of dosing, resulting in doses ranges of 22.0–36.8 mg/lb (48.3–81.0 mg/kg) imidacloprid and 2.2–3.7 mg/lb (4.8–8.0 mg/kg) moxidectin. The following abnormal clinical signs were reported immediately following oral administration of imidacloprid and moxidectin: vomiting (one ferret) and ataxia (two ferrets). All abnormalities resolved without treatment or supportive care.

DOSAGE AND ADMINISTRATION:

For ferrets:

The recommended minimum dose for a ferret is 9 mg/lb (20 mg/kg) imidacloprid and 0.9 mg/lb (2 mg/kg) moxidectin, once a month, by topical administration.

Ferret; (lbs.)	Midamox; For Cats	Volume; (mL)	Imidacloprid; (mg)	Moxidectin; (mg)
2.0-4.4	Midamox 9	0.4	40	4

Only the 0.4 mL applicator volume (Midamox 9) should be used on ferrets.

Do not apply to irritated skin.

1. Remove the applicator from the outer pouch using scissors or fold along diagonal line to expose nick; tear back at nick.
   
2. Hold the applicator upright.
3. Tap the narrow part of the applicator to ensure the contents remain within the main body of the applicator.
   
4. Twist or snap back the tip.
5. Part the hair on the back of the ferret's neck at the base of the head, until the skin is visible. Place the tip of the applicator on the skin and squeeze the applicator several times to empty its contents completely and directly onto the skin in one spot.
   

Do not get this product in the ferret's mouth or eyes or allow the ferret to lick the application site for 30 minutes. Treatment at the base of the head will minimize the opportunity for ingestion by grooming. In households with multiple pets, keep animals separated to prevent licking of the application site. Stiff, matted hair or a damp, oily appearance of the hair may be observed at the application site on some ferrets. This is temporary and does not affect the safety or effectiveness of the product.

Heartworm Prevention: For prevention of heartworm disease, Midamox for Cats should be administered at one-month intervals. Midamox for Cats may be administered year-round or at a minimum should start one month before the first expected exposure to mosquitoes and should continue at monthly intervals until one month after the last exposure to mosquitoes. If a dose is missed and a 30-day interval between doses is exceeded, administer Midamox for Cats immediately and resume the monthly dosing schedule.

Flea Treatment: For the treatment of flea infestations on ferrets, Midamox for Cats should be administered at one-month intervals. If the ferret is already infested with fleas when the first dose of Midamox for Cats is administered, adult fleas on the ferret will be killed. However, re-infestation from the emergence of pre-existing pupae in the environment may continue to occur for six weeks or longer after treatment is initiated.

STORAGE INFORMATION:

Store below 77°F (25°C). Excursions are permitted up to 104°F (40°C) however such exposure should be minimized. Do not remove the applicator from the pouch until ready to use. Do not use after the expiry date which is stated on the carton.

HOW SUPPLIED:

Applications Per Package

3 x 0.23 mL applicators, 6 x 0.4 mL applicators, 6 x 0.8 mL applicators

Approved by FDA under ANADA # 200-721

Midamox® is a registered trademark of Norbrook Laboratories Limited

Made in Ireland

Manufactured by:
Norbrook Manufacturing Ltd.
Rossmore Industrial Estate
Monaghan, Co. Monaghan
Ireland

Distributed by:

MWI, Boise, ID

www.VetOne.net

Rev. 12/23

112684I02

Principal Display Panel – 6 Pack 0.4 mL Carton Label

NDC: 86136-026-40

5.1-9 lbs.

Midamox® for Cats

(imidacloprid + moxidectin)

Topical Solution for Cats and Ferrets

CAUTION: Federal (U.S.A.) Law restricts this drug to use
by or on the order of a licensed veterinarian.

Once-A-Month Topical Solution

For Cats

• Prevention of heartworm disease
• Kills adult fleas and is indicated for the treatment of
  flea infestations
• Treatment and control of ear mite infestations
• Treatment and control of hookworms and roundworms
• For cats and kittens 9 weeks of age and older and
  5.1 to 9 lbs.

For Ferrets:

• Prevention of heartworm disease
• Kills adult fleas and treats flea infestations
• For ferrets that weigh at least 2 lbs.

Children should not come in contact with the application
site for 30 minutes after application.

Each applicator contains 40 mg of imidacloprid and 4 mg of
moxidectin

Keep this and all
drugs out of reach
of children.

Approved by FDA
under ANADA # 200-721

SIX 0.4 mL
Applicators

Heartworm

Fleas

Hookworm

Roundworm

Ear Mites

Heartworm

Fleas

6
PACK

0.4 mL
APPLICATORS

VETone®

INGREDIENTS AND APPEARANCE

MIDAMOX FOR CATS 
imidacloprid and moxidectin solution

Product Information
Product Type	PRESCRIPTION ANIMAL DRUG	Item Code (Source)	NDC: 86136-026
Route of Administration	TOPICAL

Active Ingredient/Active Moiety
Ingredient Name	Basis of Strength	Strength
imidacloprid (UNII: 3BN7M937V8) (imidacloprid - UNII:3BN7M937V8)	imidacloprid	100 mg  in 1 mL
moxidectin (UNII: NGU5H31YO9) (moxidectin - UNII:NGU5H31YO9)	moxidectin	10 mg  in 1 mL

Packaging
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC: 86136-026-23	3 in 1 CARTON
1		0.23 mL in 1 APPLICATOR
2	NDC: 86136-026-40	6 in 1 CARTON
2		0.4 mL in 1 APPLICATOR
3	NDC: 86136-026-80	6 in 1 CARTON
3		0.8 mL in 1 APPLICATOR

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANADA	ANADA200721	03/07/2023

Labeler - MWI/VetOne (019926120)

Registrant - Norbrook Laboratories Limited (214580029)

Establishment
Name	Address	ID/FEI	Business Operations
Norbrook Manufacturing Ltd		986217040	MANUFACTURE, PACK, LABEL

Establishment
Name	Address	ID/FEI	Business Operations
Norbrook Laboratories Limited		211218325	ANALYSIS